Bio Medica Laboratories IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Day-wise Subscription (times subscribed)
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Nov 2025 |
|---|---|---|---|---|
| Revenue | 16.25 | 15.34 | 38.33 | 28.63 |
| Expense | 15.80 | 11.69 | 25.18 | 16.95 |
| Profit (PAT) | 0.33 | 2.50 | 9.79 | 8.66 |
| Total Assets | 17.57 | 19.53 | 39.12 | 65.17 |
| Company | EPS | P/E |
|---|---|---|
| Zenotech Laboratories Limited | 0.92 | - |
| Shukra Pharmaceuticals Limited | 0.22 | 47.57 |
Promoters: Mr. Mukesh Mehta and Mr. Pradeep Mehta
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 91,80,001 | 99.99% |
Strengths & Risks
- Strong institutional (QIB) demand — 15.9x.
- Revenue grew 150% in the latest reported year.
- Solid profit margin — 25.5%.
- Strong return on equity — 100%.
- Mostly fresh capital — proceeds fund the company's growth, not an exit.
- Elevated leverage — debt/equity of 1.02.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Bio Medica Laboratories is one of the leading manufacturers of parenteral medicines (injectable products) in India. The firm has been involved in developing a wide range of parenteral medicines targeting both human and animal needs. They manufacture generic medicines in the form of Liquid injections and dry powder injections, which come in various forms of packaging like ampoules and vials.
Bio Medica Laboratories Ltd., Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore),, Indore, Madhya Pradesh, 452015
| Purpose | Amount (Cr) |
|---|---|
| Repayment of Loan | 7.25 |
| Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | 24.81 |
| General Corporate Purpose | - |
Resources & Documents
Bio Medica Laboratories has set a price band of Rs 132–Rs 139 per share for an issue size of Rs 52 crore. The stock listed with a 20.00% discount versus its issue price on May 29, 2026.
Bio Medica Laboratories is one of the leading manufacturers of parenteral medicines (injectable products) in India. The firm has been involved in developing a wide range of parenteral medicines targeting both human and animal needs.
The issue is promoted by Mr. Mukesh Mehta and Mr. Pradeep Mehta with Narnolia Financial Services Ltd. acting as lead manager. Net proceeds will primarily be used towards Repayment of Loan (Rs 7 crore) and Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (Rs 25 crore).
On fundamentals, the company is posting revenue growth of 149.9%, a profit margin of 25.5%, return on equity of 99.6% in its most recent reported period. Listed peers in this segment include Shukra Pharmaceuticals Limited (P/E 47.57x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read weak — several key indicators are reading below average. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Bio Medica Laboratories IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed.
See the full Bio Medica Laboratories GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!